Literature DB >> 16410823

Gene therapy for carcinoma of the breast.

M A Stoff-Khalili1, P Dall, D T Curiel.   

Abstract

In view of the limited success of available treatment modalities for breast cancer, alternative and complementary strategies need to be developed. The delineation of the molecular basis of breast cancer provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches for carcinoma of the breast have been developed. These approaches can be divided into six broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) proapoptotic gene therapy, (4) antiangiogenic gene therapy, (5) genetic immunopotentiation, and (6) genetic modulation of resistance/sensitivity. Clinical trials for breast cancer have been initiated to evaluate safety, toxicity, and efficacy. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified and advances in vector design are realized, gene therapy will play an increasing role in clinical breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410823      PMCID: PMC1781527          DOI: 10.1038/sj.cgt.7700929

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  193 in total

1.  E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy.

Authors:  N T Ueno; D Yu; M C Hung
Journal:  Breast Cancer       Date:  2001       Impact factor: 4.239

Review 2.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 3.  Antisense oligonucleotides: basic concepts and mechanisms.

Authors:  Nathalie Dias; C A Stein
Journal:  Mol Cancer Ther       Date:  2002-03       Impact factor: 6.261

Review 4.  Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.

Authors:  Yum L Yip; Robyn L Ward
Journal:  Cancer Immunol Immunother       Date:  2001-11-24       Impact factor: 6.968

Review 5.  Cancer gene therapy: fringe or cutting edge?

Authors:  F McCormick
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

6.  Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.

Authors:  Frank Friedlos; Lawrence Davies; Ian Scanlon; Lesley M Ogilvie; Janet Martin; Stephen M Stribbling; Robert A Spooner; Ion Niculescu-Duvaz; Richard Marais; Caroline J Springer
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

7.  Systemic tumor suppression by the proapoptotic gene bik.

Authors:  Yiyu Zou; Hua Peng; Binhua Zhou; Yong Wen; Shao-Chun Wang; Eing-Mei Tsai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

8.  Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice.

Authors:  E J Lee; M Jakacka; W R Duan; P Y Chien; F Martinson; B D Gehm; J L Jameson
Journal:  Mol Med       Date:  2001-11       Impact factor: 6.354

9.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Authors:  John M Timmerman; Debra K Czerwinski; Thomas A Davis; Frank J Hsu; Claudia Benike; Zheng Mei Hao; Behnaz Taidi; Ranjani Rajapaksa; Clemens B Caspar; Craig Y Okada; Adrienne van Beckhoven; Tina Marie Liles; Edgar G Engleman; Ronald Levy
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

Review 10.  Recent trends in breast cancer incidence and mortality.

Authors:  James V Lacey; Susan S Devesa; Louise A Brinton
Journal:  Environ Mol Mutagen       Date:  2002       Impact factor: 3.216

View more
  9 in total

1.  Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene.

Authors:  William W Au; Salama Abdou-Salama; Ayman Al-Hendy
Journal:  Gynecol Oncol       Date:  2006-11-29       Impact factor: 5.482

2.  Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.

Authors:  H Yamaguchi; C-T Chen; C-K Chou; A Pal; W Bornmann; G N Hortobagyi; M-C Hung
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 3.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

5.  Design of potential siRNA molecules for T antigen gene silencing of Merkel Cell Polyomavirus.

Authors:  Kazi Muhammad Ahasanul Hoque; Md Faisal Azim; M Robin Mia; Rafidin Kayesh; Md Hazrat Ali; Md Jahidul Islam; Shahriar Kabir Shakil; Tonmay Modak Shuvra
Journal:  Bioinformation       Date:  2012-10-01

6.  Design of potential siRNA molecules for hepatitis delta virus gene silencing.

Authors:  Sarita Singh; Sunil Kumar Gupta; Anuradha Nischal; Sanjay Khattri; Rajendra Nath; Kamlesh Kumar Pant; Prahlad Kishore Seth
Journal:  Bioinformation       Date:  2012-08-24

7.  Construction and detection of the tissue-specific pINV-HPV16 E6/7 vector.

Authors:  Hui Gao; Zhengfang Huang; Chenlong Shi; Houda Li
Journal:  Oncol Lett       Date:  2014-11-25       Impact factor: 2.967

8.  An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent.

Authors:  Hai-Jing Zhong; Lihua Lu; Ka-Ho Leung; Catherine C L Wong; Chao Peng; Siu-Cheong Yan; Dik-Lung Ma; Zongwei Cai; Hui-Min David Wang; Chung-Hang Leung
Journal:  Chem Sci       Date:  2015-07-30       Impact factor: 9.825

9.  AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: a preliminary study.

Authors:  Ali M Rad; A S M Iskander; Branislava Janic; Robert A Knight; Ali S Arbab; Hamid Soltanian-Zadeh
Journal:  BMC Biotechnol       Date:  2009-03-27       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.